Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants

Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled

Read more at globenewswire.com